Adds CFO quote on 2026 tariff impact

By Simon Ferdinand Eibach

Gdansk, May 6 (Reuters) - Swiss-American eye care company Alcon ALCC.S reported a 10% rise in its quarterly revenue, citing recent product launches as the main drivers.

• Alcon's net sales rose to $2.69 billion in the first quarter of 2026 from $2.45 reported a year earlier.

• Sales missed estimates of $2.71 billion by analysts polled by LSEG, with net sales in the implantables segment almost stagnant due to competitive pressures.

• Shares of Alcon opened down 4.67% at 0700 GMT, with Vontobel analysts pointing to soft cataract markets.

• Alcon's operating earnings amounted to $292 million in the first quarter, falling 32% from a year earlier.

• The company hiked its full-year guidance for diluted earnings per share growth to 10%-13% from 9%-12%, as it announced a $1.5 billion share repurchase program with a plan to cancel the acquired shares.

• In an investor webcast, Finance Chief Timothy Stonesifer said the company cut its assumed average tariff rate on U.S. imports for the remainder of the year to 10% from 15%, resulting in a $25 million reduction in projected tariff-related expenses for 2026.

• Alcon launched 10 new products in the first quarter of 2026, including Clareon TruPlus IOL, the next generation of monofocal and toric lenses for cataract surgery.